Search results for "fibrinogen"

showing 10 items of 230 documents

Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia

1992

Abstract The effect of gemfibrozil on lipidic, coagulative, and fibrinolytic pattern was studied in 20 patients with primary type IV hyperlipoproteinemia. After a 4-week stabilization period during which administration of lipid-lowering drugs was stopped and an isocaloric diet (20% protein, 30% fat, and 50% carbohydrates) was prescribed, 20 patients (12 men and 8 women; mean age, 38 ± 4 years; body mass index, 23.4 ± 1.5) suffering from primary hypertriglyceridemia were included in this study and treated for a 12-week period with gemfibrozil (600 mg BID). Every 4 weeks the following parameters were checked: glycemia, triglycerides, total cholesterol, high density lipoprotein-cholesterol, to…

Pharmacologymedicine.medical_specialtyFactor VIIbusiness.industrymedicine.medical_treatmentHypertriglyceridemiaAntithrombinmedicine.diseaseFibrinogenchemistry.chemical_compoundEndocrinologychemistryHemostasisInternal medicineFibrinolysismedicineGemfibrozillipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatormedicine.drugCurrent Therapeutic Research
researchProduct

The Internal Dynamics of Fibrinogen and Its Implications for Coagulation and Adsorption

2015

Fibrinogen is a serum multi-chain protein which, when activated, aggregates to form fibrin, one of the main components of a blood clot. Fibrinolysis controls blood clot dissolution through the action of the enzyme plasmin, which cleaves fibrin at specific locations. Although the main biochemical factors involved in fibrin formation and lysis have been identified, a clear mechanistic picture of how these processes take place is not available yet. This picture would be instrumental, for example, for the design of improved thrombolytic or anti-haemorrhagic strategies, as well as, materials with improved biocompatibility. Here, we present extensive molecular dynamics simulations of fibrinogen w…

Plasminmedicine.medical_treatmentAllosteric regulationPlasma protein bindingMolecular Dynamics SimulationFibrinogenFibrinCellular and Molecular NeuroscienceFibrinolysisGeneticsmedicineHumanslcsh:QH301-705.5Molecular BiologyBlood CoagulationEcology Evolution Behavior and SystematicsIntegrin bindingEcologybiologyChemistryComputational BiologyFibrinogenlcsh:Biology (General)Computational Theory and MathematicsCoagulationBiochemistryModeling and Simulationbiology.proteinAdsorptionmedicine.drugResearch ArticleProtein BindingPLoS Computational Biology
researchProduct

Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human?

2010

Acute liver failure (ALF) is defined as the abrupt loss of hepatic cellular function in a patient without pre-existing liver disease, with the subsequent development of coagulopathy, jaundice and encephalopathy. It remains one of the most challenging medical emergencies, due to the multiorgan nature of the disease, the rapid evolution of the clinical condition and the need for multidisciplinary supportive interventions in order to assess the necessity for liver transplantation (LT) correctly.1 Despite different causes of ALF, the mode of cell death typically follows one of two patterns: necrosis or apoptosis; apoptosis is manifest by nuclear and cytoplasmic shrinkage without disturbance of …

Programmed cell deathNecrosismedicine.medical_treatmenthepassocinLiver transplantationProinflammatory cytokineTranslational Research BiomedicalLiver diseaseFulminant hepatic failureSpecies SpecificitymedicineAnimalsHumansbusiness.industryLiver cellGastroenterologyFibrinogenLiver Failure Acutemedicine.diseaseRecombinant ProteinsNeoplasm ProteinsRatsDisease Models AnimalCytokineImmunologymedicine.symptombusiness
researchProduct

The impact of whole blood processing and freezing conditions on the quality of therapeutic plasma prepared from whole blood

2014

Background The quality of whole blood (WB)-derived plasma preparations has been the subject of several studies, but there has been a lack of robust, comparative data for the different methods of processing and freezing. Study Design and Methods Six WB-derived plasma units were pooled and split (n = 16) and frozen within either 8 or 24 hours after WB collection, stored at 4°C or at room temperature (RT), and then frozen either slowly at −20°C or rapidly to below −30°C. Plasma units were tested for fibrinogen, Factor (F)V, FVII, FVIII, FXI, and von Willebrand factor (VWF), protein C (PC), protein S (PS) activity and free PS, prothrombin time, and partial thromboplastin time. Results FVIII was…

Prothrombin timemedicine.medical_specialtymedicine.diagnostic_testbiologyChemistryImmunologyHematologyPlasmaFibrinogenProtein SSurgeryAndrologyVon Willebrand factorhemic and lymphatic diseasesmedicinebiology.proteinImmunology and AllergyProtein CWhole bloodmedicine.drugPartial thromboplastin timeTransfusion
researchProduct

D-Dimer, Thrombin-Antithrombin III-Komplex (TAT) und Prothrombinfragment 1+2 (PTF)

1997

Two groups of 15 patients each with disseminated intravascular coagulation in association with septic disease were treated with low-molecular-weight heparin (lmw-heparin) in different dosages (group I: 1.5-5 IE/kg body weight (BW) per hour; group II: 8-15 IE/kg BW). We studied the levels of D-dimer, thrombin-antithrombin III complex (TAT), prothrombin fragments 1 and 2 (PTF), and global tests of coagulation like prothrombin time (PT), activated partial thromboplastin time (PTT), thrombin time (TT) and platelet count, plasminogen activation (PA) and fibrinogen concentration to estimate the success of heparin therapy in the two groups. TT and fibrinogen concentration were not suitable to foll…

Prothrombin timemedicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classbusiness.industryPROTHROMBIN FRAGMENT 1.2Low molecular weight heparinGeneral MedicineHeparinThrombin timeFibrinogenAnesthesiology and Pain MedicineEndocrinologyInternal medicineD-dimermedicinebusinessmedicine.drugPartial thromboplastin timeDer Anaesthesist
researchProduct

FVIII production by human lung microvascular endothelial cells

2006

While extrahepatic factor VIII (FVIII) synthesis suffices for hemostasis, the extrahepatic production sites are not well defined. We therefore investigated the ability of the human lungs to produce FVIII. Lungs from heart-beating donors who were declined for transplantation were perfused and ventilated in an isolated reperfusion model for 2 hours. A progressive accumulation of FVIII and von Willebrand factor (VWF) was recorded in the perfusion medium in 3 of 4 experiments. By contrast, factor V, fibrinogen, and immunoglobulin G (IgG) levels remained constant during the perfusion period, indicating that the accumulation of FVIII and VWF was not due to diffusion from the intercellular medium …

Pulmonary Circulationcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyEndotheliumanimal diseasesImmunologyIn Vitro TechniquesFibrinogenBiochemistryImmunoglobulin GMicrocirculationVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineHumansLungFactor VIIILungbiologybusiness.industryMicrocirculationEndothelial CellsCell BiologyHematologyTransplantationKineticsEndocrinologymedicine.anatomical_structureHemostasisReperfusionImmunologybiology.proteinEndothelium Vascularbusinessmedicine.drugBlood
researchProduct

Efficacy of TachoSil patches in controlling Dacron suture-hole bleeding after abdominal aortic aneurysm open repair

2009

Abstract Purpose The aim of this study is evaluate the efficacy of TachoSil® patches in controlling suture-hole bleeding after elective infrarenal abdominal aortic aneurysm (AAA) replacement with Dacron graft. Materials and methods Patients undergoing elective replacement of infrarenal AAA with Dacron grafts were prospectively randomized to TachoSil® patches (Group I) or standard compression with surgical swabs (Group II). We evaluated time to haemostasis, blood loss during the operation, blood loss after cross-clamp removal, duration of operation, drain volume, requirement for blood transfusion and surgeons rating of efficacy. Results Twenty patients were randomized (10 patients in each tr…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyBlood transfusionmedicine.medical_treatmentlcsh:SurgeryBlood Loss Surgicalsuture hole-bleedingSettore MED/22 - Chirurgia VascolareHemostaticslcsh:RD78.3-87.3Aortic aneurysmBlood Vessel Prosthesis Implantationabdominal aortic aneurysmmedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overSuturesbusiness.industryThrombinFibrinogenlcsh:RD1-811General MedicineTachoSilMiddle Agedmedicine.diseaseAbdominal aortic aneurysmSurgeryCardiac surgeryopen repairDrug CombinationsTreatment Outcomelcsh:AnesthesiologyCardiothoracic surgeryAnesthesiaFemaleSurgerybusinessCardiology and Cardiovascular MedicineAbdominal surgeryAortic Aneurysm AbdominalResearch Article
researchProduct

Dermatopatología de la oclusión intraluminal vascular: parte I (trombos)

2021

Resumen: La patología vascular oclusiva es causante de diversas y variadas manifestaciones clínicas, algunas de las cuales son de catastróficas consecuencias para el paciente. Sin embargo, las causas de tal oclusión son muy variadas, extendiéndose desde trombos por acción descontrolada de los mecanismos de coagulación, hasta anomalías de los endotelios de los vasos u oclusión por materiales extrínsecos. En una serie de dos artículos hacemos una revisión de las principales causas de oclusión vascular, resumiendo sus manifestaciones clínicas principales y los hallazgos histopatológicos fundamentales. Esta primera parte corresponde a las oclusiones vasculares que cursan con trombos. Abstract: …

Purpura fulminansCryoagglutininsThrombosisDermatologyGeneral MedicineRC31-1245030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCryoglobulinemiaRL1-803030220 oncology & carcinogenesisEcthyma gangrenosumCryofibrinogenemiaInternal medicineActas Dermo-Sifiliográficas
researchProduct

Expression of the fibrinogen binding mannoprotein and the laminin receptor of Candida albicans in vitro and in infected tissues.

1996

We have previously reported a 37 kDa laminin-binding protein (p37) and a 58 kDa fibrinogen-binding mannoprotein (mp58) on the surface of Candida albicans. A few yeast cells expressed both functional receptors at the surface while germ tubes expressed a functional mp58 fibrinogen but not a functional p37 laminin receptor. These receptors were heterogeneously dispersed at the surface as shown by binding of rabbit antiserum to mp58 (PAb anti-mp58) and antiserum to the human high affinity laminin receptor. In this report we have used a dual fluorescence technique to determine if the two receptors colocalize, perhaps as part of a receptor complex. Fibrinogen was used as a probe for mp58 and poly…

Receptor complexBiologyImmunofluorescenceMicrobiologyReceptors LamininBacterial ProteinsLamininCandida albicansGeneticsmedicineAnimalsHumansReceptorCandida albicansFluorescent Antibody Technique IndirectMolecular BiologyAntibodies FungalAntiserumMembrane Glycoproteinsmedicine.diagnostic_testBinding proteinCandidiasisFibrinogen bindingFibrinogenbiology.organism_classificationMolecular biologyImmunohistochemistryBiochemistrybiology.proteinRabbitsCarrier ProteinsFEMS microbiology letters
researchProduct

Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatom…

1998

Abstract Interleukin 6 (IL-6) belongs to a family of cytokines using receptors sharing a common signal-transducing chain, gp130 and containing a specific ligand-binding chain (IL-6Rα). It was shown that both the membrane-bound and the soluble form (sIL-6R) of this ligand specific receptor chain occurs naturally. The soluble form of IL-6 receptor was found to be able to associate with the membrane-bound gp130 and to generate active IL-6 receptor complex capable of inducing signal transduction. This study on a human hepatoma cell line and primary rat hepatocytes examined how the effectiveness of IL-6 is modified by the presence of soluble IL-6 receptor and whether the sIL-6R in the absence of…

Receptor complexCarcinoma HepatocellularJUNBProto-Oncogene Proteins c-junImmunologyBiologyBiochemistryPolymerase Chain Reactionhemic and lymphatic diseasesGene expressionTumor Cells CulturedImmunology and AllergyAnimalsHumansRNA MessengerReceptorMolecular BiologyTranscription factorCells CulturedFibrinogenHematologyGlycoprotein 130Molecular biologyReceptors Interleukin-6RatsGene Expression RegulationLiverSolubilityInterleukin-6 receptorSignal transductionCytokine
researchProduct